Icahn School of Medicine at Mount Sinai

EDAP Announces Third Quarter 2023 Financial Results

Retrieved on: 
Jeudi, novembre 9, 2023
University of Zurich, AAGL, Hospital, EUR, USD, Overalls, Cleveland Clinic, International Symposium on Endovascular Therapy, Operating cost, EDT, Teaching hospital, University of Florida, Icahn School of Medicine at Mount Sinai, EDAP, League of European Research Universities, Prostate cancer, DACH, League, Marketing, Immunotherapy, University, Investment, Patient, TMS, Congress, Conference, Endo, Research, Growth, SEP, European Society of Gynaecological Oncology, Total, Poster, Lithotripsy, Mount Sinai Hospital, Randomized controlled trial, Pharmaceutical industry, Medical imaging, Film industry, Video game, Lithium, Medicine, Distribution, Urology

- Strong Q3 2023 U.S. Focal One® HIFU procedure growth of +150% year-over-year -

Key Points: 
  • - Strong Q3 2023 U.S. Focal One® HIFU procedure growth of +150% year-over-year -
    - Announces immunotherapy clinical research collaboration with Mount Sinai, Department of Urology -
    - Company to host conference call and webcast today, Thursday, November 9th at 8:30 am EDT -
    LYON, France, November 9, 2023 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited financial results for the third quarter ending September 30, 2023.
  • The decrease was driven by 1 Focal One system sold in the third quarter 2023 versus 3 systems sold in the third quarter of 2022.
  • Operating loss for the third quarter of 2023 was EUR 5.6 million (USD 6.0 million), compared to an operating loss of EUR 2.1 million (USD 2.2 million) in the third quarter of 2022.
  • A conference call and webcast to discuss the third quarter 2023 financial results will be hosted Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financial Officer and Ken Mobeck, Chief Financial Officer of the U.S. subsidiary, today, Thursday, November 9th, 2023, at 8:30am EDT.

The Paul G. Allen Frontiers Group announces Allen Discovery Center for Neuroimmune Interactions at Icahn School of Medicine at Mount Sinai

Retrieved on: 
Jeudi, novembre 9, 2023
Allergy, Nervous system, Inflammation, Icahn School of Medicine at Mount Sinai, Allen Institute, Innovation, Health, Autoimmunity, Physiology, Skin, Infection, NYU, Metabolism, Inflammatory bowel disease, Lung, ADC, Disease, Yale University, Immune system, Paul G. Allen Frontiers Group, Biology, Immunity, Sensation, Peripheral nervous system, Partnership, Nutrition, Brain, Cancer, Neuroinflammation, Weill Cornell Medicine, Map, Pharmaceutical industry, Research, Dermatology, Science, Medicine

SEATTLE, Nov. 9, 2023 /PRNewswire/ -- The Paul G. Allen Frontiers Group, a division of the Allen Institute, today announced the launch of the Allen Discovery Center (ADC) for Neuroimmune Interactions at the Icahn School of Medicine at Mount Sinai. The research team will comprehensively define and map the interactions between the nervous system and the immune system that take place distant from the brain, such as at the skin, lung, and gut surfaces, and analyze how these interactions relay a variety of sensations back to the brain and regulate organ physiology and tissue immune responses.

Key Points: 
  • A multidisciplinary research center to define, map, and understand the health consequences of interactions between the nervous system and the immune system
    SEATTLE, Nov. 9, 2023 /PRNewswire/ -- The Paul G. Allen Frontiers Group, a division of the Allen Institute, today announced the launch of the Allen Discovery Center (ADC) for Neuroimmune Interactions at the Icahn School of Medicine at Mount Sinai.
  • The Center will bring together cutting-edge research from the worlds of neuroscience and immunology.
  • This Allen Discovery Center is led by Dr. Brian S. Kim of Mount Sinai and Dr. David Artis of Weill Cornell Medicine.
  • The Allen Discovery Center for Neuroimmune Interactions is funded at $10 million over four years by the Paul G. Allen Family Foundation, with a total potential for $20 million over eight years.

Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Mercredi, novembre 8, 2023
Research, MADRS, Ageing, MDD, DBP, DSM-IV codes, Icahn School of Medicine at Mount Sinai, Neurocrine, Neurocrine Biosciences, JAMA Neurology, OLE, MPC, Mount Sinai, SCN8A, Webcast, Seizure, FOS, Safety, Epilepsy, Generalized tonic–clonic seizure, Patient, Grammatical mood, Pharmaceutical industry, Cryptocurrency, Xenon

VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • Xenon anticipates that patient enrollment in X-TOLE2 will be completed in the second half of 2024.
  • Other income for the quarter ended September 30, 2023 was $7.1 million, compared to $0.4 million for the same period in 2022.
  • Xenon will host a conference call and webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its third quarter 2023 results.

Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia

Retrieved on: 
Mercredi, novembre 8, 2023
Research, Associate, Life, Internet access, Congress, Icahn School of Medicine at Mount Sinai, Psychiatry, Neurocrine Biosciences, Mount Sinai, Student, TD, Tardive dyskinesia, Patient, Diagnosis, Somatic symptom disorder, SAN, Nursing, Pharmaceutical industry

SAN DIEGO, Nov. 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the availability of DISCOVER TD ™, an interactive digital tool designed to help healthcare providers learn about and identify tardive dyskinesia.

Key Points: 
  • SAN DIEGO, Nov. 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the availability of DISCOVER TD ™, an interactive digital tool designed to help healthcare providers learn about and identify tardive dyskinesia.
  • Each avatar presents various manifestations of tardive dyskinesia (TD) or other drug-induced movement disorders and is complete with a unique patient history.
  • "TD can be a significant burden for patients already managing an underlying mental illness," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.
  • The tool will be available for demonstration at the Neurocrine Medical booth at the 2023 NEI Congress , November 9–12 in Colorado Springs, Colo.
    Dr. Mercedes Perez-Rodriguez is a paid consultant for Neurocrine Biosciences, Inc.

BPGbio Wins 2023 BioTech Breakthrough Award for Therapeutics Platform of The Year

Retrieved on: 
Mercredi, novembre 8, 2023
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, Other Science, Drug discovery, GBM, Harvard Medical School, AstraZeneca, CIA, Netherlands Architecture Institute, Biomarker, Rare, Therapy, Government, Oak Ridge National Laboratory, United States Department of Defense, Supercomputing in India, Carcinoma, Icahn School of Medicine at Mount Sinai, HPC, Organization, SCC, Research, Prostate cancer, Glioblastoma, Liver disease, Multimedia, Medicine, Biology, EB, Neurology, Breast cancer, Pancreatic cancer, Sanofi, AI, ORNL, Mount Sinai, Patient, Epidermolysis bullosa, Sarcopenia, Pharmaceutical industry, Medical device, Neuroscience

View the full release here: https://www.businesswire.com/news/home/20231108370629/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231108370629/en/
    BPGbio named Therapeutics Platform of the Year by Biotech Breakthrough Awards program.
  • The award recognizes BPGbio’s success leveraging their NAi Interrogative Biology Platform to develop late-stage therapeutics and diagnostics for some of the most challenging diseases.
  • “We are honored that BPGbio has won the Therapeutics Platform of the Year from BioTech Breakthrough, a massive achievement for our employees and research partners.
  • BPGbio, our ‘Therapeutics Platform of the Year’ winner, is proving the value of AI in drug discovery for the future of medicine,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards.

American Brain Tumor Association Announces $1.3 Million in New Funding to Accelerate Adult and Pediatric Brain Tumor Research

Retrieved on: 
Mercredi, novembre 8, 2023
Soma, American Brain Tumor Association, Biomarker, Neuro, History, MD, Soma Sengupta, ABTA, Research, Chapel Hill, Mount Sinai, Brain, DNA repair, Icahn School of Medicine at Mount Sinai, Patient, Doctor of Philosophy, Joel, DNA, Medical imaging, Pharmaceutical industry, Citrus

CHICAGO, Nov. 8, 2023 /PRNewswire/ -- The American Brain Tumor Association (ABTA) today announced the funding of $1.37 million towards 23 new research grants to advance brain tumor science and treatments, across all brain tumor types and ages. Dedicated to advancing the field of neuro-oncology and accelerating the discovery of life-saving treatments, the ABTA is proud to have invested more than $35 million, to approximately 700 researchers and 800 projects, to date.

Key Points: 
  • CHICAGO, Nov. 8, 2023 /PRNewswire/ -- The American Brain Tumor Association (ABTA) today announced the funding of $1.37 million towards 23 new research grants to advance brain tumor science and treatments, across all brain tumor types and ages.
  • ABTA's high-risk, high-reward research grants have contributed to significant breakthroughs in treating brain tumors.
  • This year's slate of research projects investigates biomarkers, DNA damage and repair mechanisms, gene therapies, and more, across adult and pediatric primary brain tumors and metastatic brain cancers.
  • Research Collaboration Grants are two-year, $200,000 grants awarded for multi-investigator and multi-institutional brain tumor collaborative research projects.

Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board

Retrieved on: 
Lundi, novembre 6, 2023
Haematopoietic system, Rachel Haurwitz, Multiple myeloma, Hematology, CRISPR, Jagannath, Medicine, Abstract, Icahn School of Medicine at Mount Sinai, University, Reindeer, Mount Sinai School, MD Anderson Cancer Center, Patient, University of Arkansas, Oncology, Medical device, MD

BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) --  Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sundar Jagannath, MD, to its scientific advisory board. With four decades of experience, Dr. Jagannath is a renowned expert in bone marrow transplantation and treating patients with multiple myeloma, and he is the director of the Center of Excellence for Multiple Myeloma at The Tisch Cancer Institute and professor of medicine, hematology and medical oncology, at Mount Sinai School of Medicine, New York.

Key Points: 
  • BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sundar Jagannath, MD, to its scientific advisory board .
  • “We are honored to have Dr. Jagannath join our scientific advisory board.
  • “Dr.
  • We urgently need such treatment options for patients living with relapsed or refractory multiple myeloma.”

Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States

Retrieved on: 
Mardi, octobre 31, 2023
Associate, NYSE, Cardiac electrophysiology, Overland Park Regional Medical Center, Robotics, Physician, Icahn School of Medicine at Mount Sinai, Electrophysiology, Arrhythmia, Banner - University Medical Center Phoenix, Weill Cornell Medical Center, Heart Rhythm, Workflow, Patient, Diagnosis, Medical device, Stereotaxis, Medicine

ST. LOUIS, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the United States have been treated successfully utilizing Abbott’s EnSite™ X EP System integrated with Stereotaxis’ Robotic Magnetic Navigation System.

Key Points: 
  • ST. LOUIS, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the United States have been treated successfully utilizing Abbott’s EnSite™ X EP System integrated with Stereotaxis’ Robotic Magnetic Navigation System.
  • The integration of Abbott’s leading cardiac mapping system and Stereotaxis’ advanced robotic technology, first announced at Heart Rhythm 2023, combines highly detailed real-time diagnostic information with the unprecedented precision and stability of robotics during therapy delivery.
  • The first integrated procedures in the US were completed by physicians at Weill Cornell Medical Center, Mount Sinai Morningside, Banner University Medical Center Phoenix, and Overland Park Regional Medical Center.
  • “The combined benefits of advanced mapping and robotic technologies allows us to envision a new era of cardiac care where personalized therapy is designed and delivered to each individual patient.

Clinical Consensus on Kerecis Fish-Skin Grafts to be Presented at the SAWC Wound Conference

Retrieved on: 
Vendredi, novembre 3, 2023
Surgery, Medical Devices, Alternative Medicine, Other Health, Health, Iceland, SAWC, VLU, Dicarboxylic acid, DFU, Wound healing, Use, Icahn School of Medicine at Mount Sinai, Treatment, Skin, CWSP, Julius, Multimedia, DPM, Abstract, Caesars Palace, Whaling, MD, Kerecis

SAWC – Kerecis today announced the publication of a multi-disciplinary clinical consensus about the utilization of fish skin grafts on complex wounds.

Key Points: 
  • SAWC – Kerecis today announced the publication of a multi-disciplinary clinical consensus about the utilization of fish skin grafts on complex wounds.
  • The consensus paper will be presented at a CME/CPME/CE-accredited symposium, which will take place Saturday, November 4, from 11:30 am to 12:30 pm in Milano VII-VIII, Caesars Palace, Las Vegas at the SAWC wound conference.
  • View the full release here: https://www.businesswire.com/news/home/20231103279415/en/
    Kerecis' fish-skin grafts are available in various shapes and sizes, such as Kerecis Shield, as shown.
  • The SAWC conference accepted 36 investigator-initiated poster abstracts that discuss the use of fish-skin grafts in various types of wounds and reconstructive operations.

Mount Sinai Researchers Receive $7 Million to Improve Outcomes for High-risk Blood Cancer Patients From the Multiple Myeloma Research Foundation

Retrieved on: 
Jeudi, novembre 2, 2023
Multiple myeloma, CAR, Icahn Genomics Institute, Black, Associate, Washington University in St. Louis, Therapy, CRISPR, Genetics, Bone marrow, Icahn School of Medicine at Mount Sinai, Early Prostate Cancer (clinical programme), Translational research, Doctor of Philosophy, Multiple Myeloma Research Foundation, Research, MAC, Stanford University Medical Center, Mount Sinai Health System, University of California, San Francisco, Genomics, Growth, Disease, MMRF, Immunotherapy, University, Gene, Hackensack University Medical Center, San Francisco, Cancer, Patient, Marc, Pharmaceutical industry, Vaccine, MD

NEW YORK, Nov. 2, 2023 /PRNewswire-PRWeb/ -- The Mount Sinai Health System has received a $7 million grant from the Multiple Myeloma Research Foundation for a three-year project that aims to fast-track novel translational concepts to improve outcomes for people with high risk myeloma, the second most common blood cancer in the United States.

Key Points: 
  • Multiple myeloma is a blood cancer that develops in the bone marrow and can spread throughout the body.
  • In 2023, more than 35,000 Americans are projected to be diagnosed with multiple myeloma and approximately 12,000 will lose their lives.
  • Researchers hope to uncover the full landscape of genomic, proteomic and immune differences between high- and standard-risk multiple myeloma patients.
  • "The three exciting programs we selected each have potential to answer fundamental questions about multiple myeloma and help advance rational treatments for this cancer."